Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Coe, Bradley P ^a   Thu, Kelsie L ^a   Aviel Ronen, Sarit ^b   Vucic, Emily A ^a   Gazdar, Adi F ^c   Lam, Stephen ^a   Tsao, Ming Sound ^d,e   Lam, Wan L ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b SHEBA MEDICAL CENTER   (Israel)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e Departments of Radiation Oncology and Medical Biophysics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; E2F GENE; E2F1 GENE; E2F3 GENE; EZH2 GENE; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOGENE; RB1 GENE; RNA SEQUENCE; TRANSCRIPTION REGULATION;

CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; DNA METHYLATION; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; TRANSCRIPTIONAL ACTIVATION;

EID: 84881561661     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071670     Document Type: Article

References (60)

1. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC, (2007) Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 12: 1096-1104.
2. Simon GR, Wagner H, (2003) Small cell lung cancer. Chest 123: 259S-271S.
3. Socinski MA, Bogart JA, (2007) Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol 25: 4137-4145.
4. Weinmann M, Jeremic B, Bamberg M, Bokemeyer C, (2003) Treatment of lung cancer in elderly part II: small cell lung cancer. Lung Cancer 40: 1-16.
5. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, et al. (2012) Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44: 1104-1110.
6. Rossi A, Maione P, Colantuoni G, Guerriero C, Gridelli C, (2004) The role of new targeted therapies in small-cell lung cancer. Crit Rev Oncol Hematol 51: 45-53.
7. Rostad H, Naalsund A, Jacobsen R, Strand TE, Scott H, et al. (2004) Small cell lung cancer in Norway. Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg 26: 782-786.
8. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, et al. (2012) Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44: 1111-1116.
9. Walker S, (2003) Updates in small cell lung cancer treatment. Clin J Oncol Nurs 7: 563-568.
10. Pao W, Girard N, (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180.
11. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, et al. (2012) Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2: 798-811.
12. Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, et al. (2006) Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer 54: 155-162.
13. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, et al. (2004) Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363: 775-781.
14. Lee J, Park CK, Park JO, Lim T, Park YS, et al. (2008) Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy. Clin Cancer Res 14: 82-88.
15. Xu G, Livingston DM, Krek W, (1995) Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci U S A 92: 1357-1361.
16. Coe BP, Lockwood WW, Girard L, Chari R, Macaulay C, et al. (2006) Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer 94: 1927-1935.
17. Coe BP, Lee HL, Chi B, Girard L, Minna JD, et al. (2005) Gain of a region on 7p22.3, containing MAD1L1, is the Most Frequent Event in Small Cell Lung Cancer Cell Lines. Genes Chromosomes Cancer In Press.
18. Thu KL, Pikor LA, Chari R, Wilson IM, Macaulay CE, et al. (2011) Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer. J Thorac Oncol 6: 1521-1529.
19. Lonergan KM, Chari R, Deleeuw RJ, Shadeo A, Chi B, et al. (2006) Identification of novel lung genes in bronchial epithelium by serial analysis of gene expression. Am J Respir Cell Mol Biol 35: 651-661.
20. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, et al. (2009) Genome-wide DNA methylation profiling using Infinium(R) assay. Epigenomics 1: 177-200.
21. Du P, Kibbe WA, Lin SM, (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548.
22. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, et al. (2008) Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 4: e1000242.
23. Eppig JT, Blake JA, Bult CJ, Kadin JA, Richardson JE, (2012) The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res 40: D881-886.
24. Chari R, Lonergan KM, Pikor LA, Coe BP, Zhu CQ, et al. (2010) A sequence-based approach to identify reference genes for gene expression analysis. BMC Med Genomics 3: 32.
25. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, et al. (2010) Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11: 587.
26. Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, et al. (2010) Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med 7: e1000315.
27. Sattler M, Salgia R, (2003) Molecular and cellular biology of small cell lung cancer. Semin Oncol 30: 57-71.
28. Du W, Pogoriler J, (2006) Retinoblastoma family genes. Oncogene 25: 5190-5200.
29. Lees JA, Saito M, Vidal M, Valentine M, Look T, et al. (1993) The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 13: 7813-7825.
30. Caputi M, Russo G, Esposito V, Mancini A, Giordano A, (2005) Role of cell-cycle regulators in lung cancer. J Cell Physiol 205: 319-327.
31. Lomazzi M, Moroni MC, Jensen MR, Frittoli E, Helin K, (2002) Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry. Nat Genet 31: 190-194.
32. Arriola E, Canadas I, Arumi M, Rojo F, Rovira A, et al. (2008) Genetic changes in small cell lung carcinoma. Clin Transl Oncol 10: 189-197.
33. Mori N, Yokota J, Akiyama T, Sameshima Y, Okamoto A, et al. (1990) Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene 5: 1713-1717.
34. Grimaud C, Negre N, Cavalli G, (2006) From genetics to epigenetics: the tale of Polycomb group and trithorax group genes. Chromosome Res 14: 363-375.
35. Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, et al. (2006) The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107: 2170-2179.
36. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874.
37. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, et al. (2005) Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75: 252-257.
38. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, et al. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J 22: 5323-5335.
39. Breuer RH, Snijders PJ, Smit EF, Sutedja TG, Sewalt RG, et al. (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6: 736-743.
40. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT, (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67: 547-556.
41. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, et al. (2007) Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46: 200-208.
42. Hinz S, Kempkensteffen C, Christoph F, Hoffmann M, Krause H, et al. (2007) Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder. J Cancer Res Clin Oncol.
43. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606-11611.
44. Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, et al. (2008) The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88: 873-882.
45. Hu S, Yu L, Li Z, Shen Y, Wang J, et al. (2010) Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10: 788-795.
46. Karanikolas BD, Figueiredo ML, Wu L, (2010) Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 70: 675-688.
47. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, et al. (2007) A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67: 10657-10663.
48. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, et al. (2002) Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 99: 12963-12968.
49. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, et al. (2004) Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027-9034.
50. Easwaran H, Johnstone SE, Van Neste L, Ohm J, Mosbruger T, et al. (2012) A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 22: 837-849.
51. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.
52. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-236.
53. Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP (2012) The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene.
54. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, et al. (2011) Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 3: 75ra25.
55. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, et al. (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 12: R36.
56. Bondzi C, Litz J, Dent P, Krystal GW, (2000) Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells. Cell Growth Differ 11: 305-314.
57. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, et al. (2007) Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer 97: 368-377.
58. Rozengurt E, (1999) Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Curr Opin Oncol 11: 116-122.
59. Shan L, Aster JC, Sklar J, Sunday ME, (2007) Notch-1 regulates pulmonary neuroendocrine cell differentiation in cell lines and in transgenic mice. Am J Physiol Lung Cell Mol Physiol 292: L500-509.
60. Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tumer Z, et al. (2006) Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer 52: 281-290.